1879 studies found for:    5-HT2A
Show Display Options
Rank Status Study
1 Recruiting Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors
Condition: Healthy
Interventions: Drug: Citalopram and Pindolol;   Dietary Supplement: Acute tryptophan depletion
2 Completed Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
Condition: Schizophrenia
Intervention: Drug: quetiapine
3 Completed A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377
Condition: Healthy
Intervention: Drug: PF-05212377
4 Completed SPECT Study With SB-773812 In Schizophrenic Patients
Condition: Schizophrenia
Intervention: Drug: SB773812 (risperidone)
5 Completed A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers
Condition: Healthy
Intervention: Drug: JNJ-40411813
6 Completed An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
Condition: Depressive Disorder
Intervention: Drug: MDL100.907
7 Completed Trazodone for SSRI-sexual Dsyfunction
Condition: Sexual Dysfunction
Interventions: Drug: Trazodone;   Drug: Placebo
8 Completed Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging
Conditions: Amphetamine-Related Disorders;   Amphetamine Abuse
Intervention: Drug: dexfenfluramine
9 Completed Safety and Efficacy of APD356 in the Treatment of Obesity
Condition: Obesity
Intervention: Drug: APD356
10 Completed Safety and Efficacy of APD356 in the Treatment of Obesity
Condition: Obesity
Intervention: Drug: APD356
11 Completed ACP-103 to Treat Parkinson's Disease
Conditions: Parkinson's Disease;   Dyskinesias
Interventions: Drug: Intravenous Levodopa;   Drug: ACP-103
12 Completed Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
Conditions: Schizophrenia;   Diabetes;   Insulin Resistance
Interventions: Procedure: Glucose clamp technique;   Drug: Amisulpride;   Drug: Olanzapine;   Drug: Placebo
13 Completed Predicting Medication Response in Obsessive Compulsive Disorder
Condition: Obsessive Compulsive Disorder
Interventions: Drug: clomipramine;   Drug: escitalopram;   Drug: duloxetine
14 Completed The Effect of Neu-P11 on Symptoms in Patients With D-IBS
Condition: Diarrhea- Irritable Bowel Syndrome
Interventions: Drug: Neu-P11;   Drug: Placebo
15 Active, not recruiting A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation
Condition: Smoking Cessation
Interventions: Drug: APD356-lorcaserin hydrochloride;   Drug: Placebo
16 Recruiting PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Brexpiprazole 1mg to 4mg
17 Completed Depression, Epinephrine, and Platelet Function
Condition: Major Depressive Disorder
Intervention: Drug: escitalopram or desipramine
18 Recruiting A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women
Conditions: PMS;   Hot Flashes
Interventions: Drug: I placebo capsule;   Drug: II RDC 0.3mg capsule;   Drug: III RDC 0.6mg capsule
19 Recruiting Phase I Study to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection
Condition: Healthy
Interventions: Drug: VVZ-149 Injection;   Drug: placebo (water for injection)
20 Completed
Has Results
Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
Conditions: Menopause;   Vasomotor Symptoms
Interventions: Drug: esmirtazapine;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years